GENERIC NAME OF THE MEDICINAL PRODUCT:
B) Carbidopa, Levodopa and Entacapone Tablets 25mg+100mg+200mg
C) Carbidopa, Levodopa and Entacapone Tablets 37.5mg+150mg+200mg
QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….12.5mg
Levodopa IP……………………………………………….50mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Quinizarine green ss
B) Carbidopa, Levodopa and Entacapone Tablets 25mg+100mg+200mg
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….25mg
Levodopa IP……………………………………………….100mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Red oxide of iron
C) Carbidopa, Levodopa and Entacapone Tablets 37.5mg+150mg+200mg
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….37.5mg
Levodopa IP……………………………………………….150mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Ponceau 4 R
THERAPEUTIC INDICATIONS:
CAUTION & SCHEDULE:
KEEP MEDICINE OUT OF REACH OF CHILDREN.
SWALLOW WHOLE DO NOT CHEW OR CRUSH
SCHEDULE: SCHEDULE H: NOT TO BE SOLD BY RETAIL WITHOUT THE PRESCRIPTION OF A NEUROLOGIST.
STORAGE & DOSAGE:
Protect from Light and moisture.
Dosage: As directed by the Neurologist.
Carbidopa, Levodopa and Entacapone Tablets 25mg+100mg+200mg Technical Specification:
| Product Name: | Carbidopa, Levodopa and Entacapone Tablets |
| Brand Name: | Generic |
| Strength: | 12.5mg+50mg+200mg, 25mg+100mg+200mg, 37.5mg+50mg+200mg |
| Dosage Form: | Tablets (Film coated) |
| Route of Administration: | Via Oral Route |
| Packing: | 10s, 30s, 100s, 500s |
| Pack Insert/Leaflet: | PIL (Patient Information Leaflet) |
| Documents: | COA, MOA, Stability Studies, GMP |
| Therapeutic use: | Anti-Parkinson, Central Nervous System |
| Indication: | Carbidopa, entacapone, and levodopa combination is used to treat Parkinson’s disease, sometimes called shaking palsy. |
| Storage: | Store below 30°C. Protect from Light and moisture. |
GENERIC NAME OF THE MEDICINAL PRODUCT:
- Carbidopa, Levodopa and Entacapone Tablets 12.5mg+50mg+200mg
- Carbidopa, Levodopa and Entacapone Tablets 25mg+100mg+200mg
- Carbidopa, Levodopa and Entacapone Tablets 37.5mg+150mg+200mg
QUALITATIVE AND QUANTITATIVE COMPOSITION:
- Carbidopa, Levodopa and Entacapone Tablets 12.5mg+50mg+200mg
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….12.5mg
Levodopa IP……………………………………………….50mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Quinizarine green ss - Carbidopa, Levodopa and Entacapone Tablets 25mg+100mg+200mg
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….25mg
Levodopa IP……………………………………………….100mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Red oxide of iron - Carbidopa, Levodopa and Entacapone Tablets 37.5mg+150mg+200mg
Each film coated tablet contains:
Carbidopa IP
Equivalent to Carbidopa anhydrous………….37.5mg
Levodopa IP……………………………………………….150mg
Entacapone IP……………………………………………200mg
Excipients…………………………………………………… q.s.
Colours: Ponceau 4 R
THERAPEUTIC INDICATIONS:
- Carbidopa, entacapone, and levodopa combination is used to treat Parkinson’s disease, sometimes called shaking palsy. Parkinson’s disease is a disorder of the central nervous system (brain and spinal cord).
CAUTION & SHEDULE:
- CAUTION: Read enclosed leaflet before use.
Keep medicine out of reach of children.
SWALLOW WHOLE DO NOT CHEW OR CRUSH - SCHEDULE: SCHEDULE H: NOT TO BE SOLD BY RETAIL WITHOUT THE PRESCRIPTION OF A NEUROLOGIST.
STORAGE & DOSAGE:
- Storage: Store below 30°C. Protect from Light and moisture.
- Dosage: As directed by the Neurologist.






